scispace - formally typeset
Search or ask a question
Institution

National Cheng Kung University

EducationTainan City, Taiwan
About: National Cheng Kung University is a education organization based out in Tainan City, Taiwan. It is known for research contribution in the topics: Population & Thin film. The organization has 49723 authors who have published 69799 publications receiving 1437420 citations. The organization is also known as: NCKU.


Papers
More filters
Journal ArticleDOI
TL;DR: The genome of biotype 1 strain V. vulnificus YJ016, an etiologic agent of human mortality from seafood-borne infections, was sequenced and a super-integron (SI) was identified, and the SI region spans 139 kbp and contains 188 gene cassettes.
Abstract: The halophile Vibrio vulnificus is an etiologic agent of human mortality from seafood-borne infections. We applied whole-genome sequencing and comparative analysis to investigate the evolution of this pathogen. The genome of biotype 1 strain, V. vulnificus YJ016, was sequenced and includes two chromosomes of estimated 3377 kbp and 1857 kbp in size, and a plasmid of 48,508 bp. A super-integron (SI) was identified, and the SI region spans 139 kbp and contains 188 gene cassettes. In contrast to non-SI sequences, the captured gene cassettes are unique for any given Vibrio species and are highly variable among V. vulnificus strains. Multiple rearrangements were found when comparing the 5.3-Mbp V. vulnificus YJ016 genome and the 4.0-Mbp V. cholerae El Tor N16961 genome. The organization of gene clusters of capsular polysaccharide, iron metabolism, and RTX toxin showed distinct genetic features of V. vulnificus and V. cholerae. The content of the V. vulnificus genome contained gene duplications and evidence of horizontal transfer, allowing for genetic diversity and function in the marine environment. The genomic information obtained in this study can be applied to monitoring vibrio infections and identifying virulence genes in V. vulnificus.

375 citations

Journal ArticleDOI
TL;DR: The demonstrated scalable fabrication, superior sensitivity over conventional sensors, and unique properties of the described strain gauges have the potential to improve existing technology and open up new fields of applications for strain sensors.
Abstract: Here we report on the fabrication and characterization of a novel type of strain gauge based on percolative networks of 2D materials. The high sensitivity of the percolative carrier transport to strain induced morphology changes was exploited in strain sensors that can be produced from a wide variety of materials. Highly reliable and sensitive graphene-based thin film strain gauges were produced from solution processed graphene flakes by spray deposition. Control of the gauge sensitivity could be exerted through deposition-induced changes to the film morphology. This exceptional property was explained through modeling of the strain induced changes to the flake–flake overlap for different percolation networks. The ability to directly deposit strain gauges on complex-shaped and transparent surfaces was presented. The demonstrated scalable fabrication, superior sensitivity over conventional sensors, and unique properties of the described strain gauges have the potential to improve existing technology and ope...

373 citations

Journal ArticleDOI
TL;DR: In this paper, the authors investigated the forced convective cooling performance of a copper microchannel heat sink with Al2O3/water nanofluid as the coolant, and the results showed that the nano-fluid-cooled heat sink outperforms the water-cooling one, having significantly higher average heat transfer coefficient and thereby markedly lower thermal resistance and wall temperature at high pumping power.

372 citations

Journal ArticleDOI
TL;DR: Afatinib shows activity in the treatment of patients with advanced lung adenocarcinoma with EGFR mutations, especially in patients with deletion 19 or L858R mutations, and should be compared with chemotherapy or other EGFR tyrosine-kinase inhibitors in EGFR-mutation-positive NSCLC.
Abstract: Summary Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of afatinib in patients with lung adenocarcinoma and EGFR mutations. Methods In this phase 2 study, we enrolled patients from 30 centres in Taiwan and the USA with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) with EGFR mutations, who had no more than one previous chemotherapy regimen for advanced disease, an Eastern Cooperative Oncology Group performance status of 0–2, and no previous treatment with EGFR tyrosine-kinase inhibitors. We tested two afatinib starting doses: 50 mg daily and subsequently 40 mg daily, introduced to establish whether tolerability could be improved with retention of anti-tumour activity. The primary endpoint was the proportion of patients with a confirmed objective response (complete response or partial response), on the basis of Response Evaluation Criteria in Solid Tumors 1.0 (independent review). This study is registered with ClinicalTrials.gov, number NCT00525148. Findings 129 patients were treated with afatinib, 99 with a starting dose of 50 mg and 30 with a starting dose of 40 mg. 79 (61%) of 129 patients had an objective response (two complete responses, 77 partial responses). 70 (66%) of the 106 patients with the two common activating EGFR mutations (deletion 19 or L858R) had an objective response, as did nine (39%) of 23 patients with less common mutations. Similar proportions of patients had an objective response when analysed by starting dose (18 [60%] of 30 patients at 40 mg vs 61 [62%] of 99 patients at 50 mg). Of the two most common adverse events (diarrhoea and rash or acne), grade 3 events were more common in patients receiving a 50 mg starting dose (22 [22%] of 99 patients for diarrhoea and 28 [28%] of 99 patients for rash or acne) than they were in those receiving a 40 mg starting dose (two [7%] of 30 patients for both diarrhoea and rash or acne); possibly treatment-related serious adverse events were also less common in patients receiving a 40 mg starting dose (two of 30 patients vs 14 of 99 patients). We recorded one possibly drug-related death (interstitial lung disease). Interpretation Afatinib shows activity in the treatment of patients with advanced lung adenocarcinoma with EGFR mutations, especially in patients with deletion 19 or L858R mutations. The efficacy of afatinib 40 mg should be compared with chemotherapy or other EGFR tyrosine-kinase inhibitors in EGFR-mutation-positive NSCLC. Funding Boehringer Ingelheim Inc.

372 citations

Journal ArticleDOI
Vassilis Angelopoulos1, P. Cruce1, Alexander Drozdov1, Eric Grimes1, N. Hatzigeorgiu2, D. A. King2, Davin Larson2, James W. Lewis2, J. M. McTiernan2, D. A. Roberts3, C. L. Russell1, Tomoaki Hori4, Yoshiya Kasahara5, Atsushi Kumamoto6, Ayako Matsuoka, Yukinaga Miyashita7, Yoshizumi Miyoshi4, I. Shinohara, Mariko Teramoto4, Jeremy Faden, Alexa Halford8, Matthew D. McCarthy9, Robyn Millan10, John Sample11, David M. Smith12, L. A. Woodger10, Arnaud Masson, A. A. Narock3, Kazushi Asamura, T. F. Chang4, C. Y. Chiang13, Yoichi Kazama14, Kunihiro Keika15, S. Matsuda4, Tomonori Segawa4, Kanako Seki15, Masafumi Shoji4, Sunny W. Y. Tam13, Norio Umemura4, B. J. Wang16, B. J. Wang14, Shiang-Yu Wang14, Robert J. Redmon17, Juan V. Rodriguez18, Juan V. Rodriguez17, Howard J. Singer17, Jon Vandegriff19, S. Abe20, Masahito Nose21, Masahito Nose4, Atsuki Shinbori4, Yoshimasa Tanaka22, S. UeNo21, L. Andersson23, P. Dunn2, Christopher M. Fowler23, Jasper Halekas24, Takuya Hara2, Yuki Harada21, Christina O. Lee2, Robert Lillis2, David L. Mitchell2, Matthew R. Argall25, Kenneth R. Bromund3, James L. Burch26, Ian J. Cohen19, Michael Galloy27, Barbara L. Giles3, Allison Jaynes24, O. Le Contel28, Mitsuo Oka2, T. D. Phan2, Brian Walsh29, Joseph Westlake19, Frederick Wilder23, Stuart D. Bale2, Roberto Livi2, Marc Pulupa2, Phyllis Whittlesey2, A. DeWolfe23, Bryan Harter23, E. Lucas23, U. Auster30, John W. Bonnell2, Christopher Cully31, Eric Donovan31, Robert E. Ergun23, Harald U. Frey2, Brian Jackel31, A. Keiling2, Haje Korth19, J. P. McFadden2, Yukitoshi Nishimura29, Ferdinand Plaschke32, P. Robert28, Drew Turner8, James M. Weygand1, Robert M. Candey3, R. C. Johnson3, T. Kovalick3, M. H. Liu3, R. E. McGuire3, Aaron Breneman33, Kris Kersten33, P. Schroeder2 
TL;DR: The SPEDAS development history, goals, and current implementation are reviewed, and its “modes of use” are explained with examples geared for users and its technical implementation and requirements with software developers in mind are outlined.
Abstract: With the advent of the Heliophysics/Geospace System Observatory (H/GSO), a complement of multi-spacecraft missions and ground-based observatories to study the space environment, data retrieval, analysis, and visualization of space physics data can be daunting. The Space Physics Environment Data Analysis System (SPEDAS), a grass-roots software development platform ( www.spedas.org ), is now officially supported by NASA Heliophysics as part of its data environment infrastructure. It serves more than a dozen space missions and ground observatories and can integrate the full complement of past and upcoming space physics missions with minimal resources, following clear, simple, and well-proven guidelines. Free, modular and configurable to the needs of individual missions, it works in both command-line (ideal for experienced users) and Graphical User Interface (GUI) mode (reducing the learning curve for first-time users). Both options have “crib-sheets,” user-command sequences in ASCII format that can facilitate record-and-repeat actions, especially for complex operations and plotting. Crib-sheets enhance scientific interactions, as users can move rapidly and accurately from exchanges of technical information on data processing to efficient discussions regarding data interpretation and science. SPEDAS can readily query and ingest all International Solar Terrestrial Physics (ISTP)-compatible products from the Space Physics Data Facility (SPDF), enabling access to a vast collection of historic and current mission data. The planned incorporation of Heliophysics Application Programmer’s Interface (HAPI) standards will facilitate data ingestion from distributed datasets that adhere to these standards. Although SPEDAS is currently Interactive Data Language (IDL)-based (and interfaces to Java-based tools such as Autoplot), efforts are under-way to expand it further to work with python (first as an interface tool and potentially even receiving an under-the-hood replacement). We review the SPEDAS development history, goals, and current implementation. We explain its “modes of use” with examples geared for users and outline its technical implementation and requirements with software developers in mind. We also describe SPEDAS personnel and software management, interfaces with other organizations, resources and support structure available to the community, and future development plans.

371 citations


Authors

Showing all 49872 results

NameH-indexPapersCitations
Yi Chen2174342293080
Yang Yang1642704144071
R. E. Hughes1541312110970
Mercouri G. Kanatzidis1521854113022
Thomas J. Smith1401775113919
Hui Li1352982105903
Gerald M. Reaven13379980351
Chi-Huey Wong129122066349
Joseph P. Vacanti11944150739
Kai Nan An10995351638
Ding-Shinn Chen10477446068
James D. Neaton10133164719
David C. Christiani100105255399
Jo Shu Chang9963937487
Yu Shyr9854239527
Network Information
Related Institutions (5)
National Taiwan University
130.8K papers, 3.3M citations

98% related

National University of Singapore
165.4K papers, 5.4M citations

93% related

University of Hong Kong
99.1K papers, 3.2M citations

92% related

Nanyang Technological University
112.8K papers, 3.2M citations

92% related

Zhejiang University
183.2K papers, 3.4M citations

91% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202373
2022315
20213,425
20203,154
20192,895
20182,764